AtriCure Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

AtriCure hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$0.77
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

May 30

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Apr 04

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

May 08

Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 11

Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Feb 18

Why AtriCure, Inc. (NASDAQ:ATRC) Could Be Worth Watching

Jan 20

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ATRC in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ATRC gestiegen sind.

Dividendenrendite im Vergleich zum Markt

AtriCure Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von ATRC im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (ATRC)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Medical Equipment)	1.8%
Analystenprognose in 3 Jahren (ATRC)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ATRC im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ATRC im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ATRC, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ATRC keine Ausschüttungen gemeldet hat.

AtriCure Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Year 2024

AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management

AtriCure, Inc. to Report Q1, 2024 Results on May 01, 2024

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

AtriCure, Inc., Annual General Meeting, May 13, 2024

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board’s Strategy Committee and Compliance, Quality and Risk Committee

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Atricure, Inc. Provides Earnings Guidance for 2024

AtriCure, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Consensus EPS estimates upgraded to US$0.70 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AtriCure, Inc. Provides Revenue Guidance for the 2023

AtriCure, Inc. to Report Q3, 2023 Results on Nov 01, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Now 24% undervalued

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Consensus estimates of losses per share improve by 15%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Atricure, Inc. Provides Revenue Guidance for the Year 2023

AtriCure, Inc. to Report Q2, 2023 Results on Jul 25, 2023

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Independent Director recently sold US$203k worth of stock

Independent Director notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Atricure, Inc. Provides Revenue Guidance for Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Independent Director exercised options to buy US$393k worth of stock.

Now 21% undervalued after recent price drop

Independent Director exercised options to buy US$799k worth of stock.

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Consensus EPS estimates fall by 31%

Price target decreased by 7.7% to US$56.33

Full year 2022 earnings: EPS exceeds analyst expectations

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

AtriCure, Inc. Announces the First Patient Treated in the LeAAPS™ Clinical Trial

AtriCure, Inc. to Report Q4, 2022 Results on Feb 21, 2023

AtriCure, Inc. Provides Earnings Guidance for 2023

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Now 21% undervalued

Price target decreased to US$57.83

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

AtriCure, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Chief Scientific Officer recently sold US$229k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Independent Director exercised options to buy US$642k worth of stock.

Insider notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AtriCure, Inc. Provides Earnings Guidance for the Full Year of 2022

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Insider notifies of intention to sell stock

Price target decreased to US$69.50

AtriCure, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Price target decreased to US$74.83

Insider notifies of intention to sell stock

Investor sentiment deteriorated over the past week

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

AtriCure, Inc. Announces the First Patient Treated in the HEAL-IST Clinical Trial